SCHEMBL424386

SCHEMBL424386

CN(C(=O)n1nnc2ccc(-c3ccc(F)cc3)cc21)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.48
GRIN2B Q13224 6/20 0.45
TRPA1 O75762 1/20 0.44
MGLL Q99685 1/20 0.44
KCNH2 Q12809 1/20 0.41
POLB P06746 2/20 0.39
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
ITK Q08881 1/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK14 Q16539 1/20 0.37
MGAM O43451 1/20 0.37
AMY1A P0DUB6 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427316 0.91 TRPV1 (0.48) TRPV1GRIN2BTRPA1MGLLKCNH2
SCHEMBL425717 0.83 TRPV1 (0.45) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL425482 0.83 TRPV1 (0.47) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL424342 0.79 TRPV1 (0.53) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL427980 0.78 MGAM (0.47) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL424622 0.78 KMT2A (0.51) TRPV1TRPA1MGLLALDH1A1MAPT
SCHEMBL427978 0.76 KCNMA1 (0.50) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL425471 0.75 TRPV1 (0.44) TRPV1TRPA1MGLLPOLBITK
SCHEMBL426739 0.75 TRPV1 (0.50) TRPV1TRPA1MGLLPOLBALDH1A1
SCHEMBL426744 0.74 TRPV1 (0.47) TRPV1TRPA1MGLLPOLBITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 TRPV1 165/4885GRIN2B 2279/4885TRPA1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.